Clinical Trials

  • Principal Investigator:

    Magdalena E Sobieszczyk, MD, MPH
    The HIV Vaccine Trials Network (HVTN), Division of AIDS (DAIDS), and Columbia University Irving Medical Center (CUIMC) are conducting a trial to learn about the safety and effectiveness of a new experimental HIV vaccine. The goal is to understand if the study products are safe to use in people living with HIV, and whether they can get the study products without being too uncomfortable. We also want to understand how people's immune systems respond to the study products, and whether stopping HIV medications changes these immune responses. There will be 2 groups in this study. Both groups will...
  • Principal Investigator:

    Marcus Rebello Pereira, MD
    In this research study, we want to find out how well patients that receive a kidney from an HIV-positive (HIV+) donor do over 10 years compared to patients who receive a kidney from an HIV-negative (HIV-) donor. This research study is for adults who are HIV+ and are being evaluated for or are waitlisted to receive a kidney transplant. It is also available for adults who are HIV+ and previously received a kidney-only transplant under a HOPE Act protocol. To take part in this study you must be willing to accept a kidney from an HIV+ or HIV- donor. If you decide not to join this study, you will...
  • Principal Investigator:

    Michael T Yin, MD
    We are doing a research study to find out if Long-Acting Injectable anti-HIV medications will be more successful than standard pills for people who have a hard time taking their HIV pills. If you are over the age of 18 years old, have been prescribed HIV medications but have had difficulty getting undetectable viral load (when the levels of virus in the bloodstream are so low that they can't be measured), you may be eligible. You may receive up to $1100 for the first 5 months of participation. Contact us to find out more about this study.
  • Principal Investigator:

    Magdalena E Sobieszczyk, MD, MPH
    We are looking for individuals over 18 years old who are interested in learning more about COVID-19 prevention research studies. We will ask you to complete a brief questionnaire to find out if you may be eligible for one of our studies. We can then schedule a phone call, teleconference, or in-person education visit so you can learn about the research we do and decide if you want to participate in one of our studies. Your responses to this questionnaire will be kept strictly confidential.
  • Principal Investigator:

    Magdalena E Sobieszczyk, MD, MPH
    Do you identify as a woman or transgender person, or do you have a non-binary gender identity? Has a medical provider ever diagnosed you with a sexually transmitted infection or recommended PrEP/another HIV prevention method? We are conducting a study to understand attitudes and preferences regarding HIV prevention methods among people who do not have HIV. The study involves taking online surveys. Some surveys are compensated. Please reach out if you are interested in hearing more about the study.
  • Principal Investigator:

    Deborah A Theodore, MD
    This is a study for people with symptoms of long COVID. We are looking for people over the age of 18 who are interested in participating in a study to understand whether a mindfulness meditation intervention can help improve symptoms of long COVID. Study participation lasts 6 months and is fully remote.
  • Principal Investigator:

    Anne-Catrin Uhlemann, MD,MPH
    We want to examine if wastewater-based surveillance of SARS-CoV-2 is a valuable tool to detect SARS-CoV-2-positive individuals on campus prior to being identified by routine individual testing. We aim to enroll CU employees and students for active surveillance of SARS-CoV-2 carriage to be able to validate waste water surveillance findings. If successful this approach might inform targeted testing and can improve safety on campus.
  • Principal Investigator:

    Magdalena E Sobieszczyk, MD, MPH
    The purpose of this study is to look at whether these study drugs improve the bodys response to human immunodeficiency virus (HIV) in people with HIV (PWH) who started antiretroviral therapy (ART) early after getting HIV-1. The study treatments we are investigating are a study treatment vaccine, a study drug called vesatolimod (VES), and two broadly neutralizing antibodies (bNAbs; antibodies are natural proteins that the body makes in response to an infection), called GS-5423 and GS-2872. None of these experimental products has been approved by the US FDA except to be used in this research...
  • Principal Investigator:

    Jason E Zucker, MD
    The purpose of this study is to evaluate how well tecovirimat works for the treatment of human monkeypox virus infection and if the study drug is safe in people. Tecovirimat is approved by the Food and Drug Administration (FDA) to treat smallpox in adults and children, but its use in this study is considered investigational. Tecovirimat has been given safely to some people with monkeypox in the recent outbreak and is currently being studied in several ongoing studies outside of the US, but none of the studies have shown whether or not this study drug works to treat monkeypox. 530 people will...
  • Principal Investigator:

    Michael T Yin, MD
    This research study is being conducted to see if HIV antiretroviral medicines that you are taking continue to work well in transgender women and other individuals identifying as female or transfeminine, but with male sex assigned at birth (referred to as transgender) when taken with feminizing hormone therapy (FHT), also known in this study as estradiol. You will receive estradiol as FHT. FHT is used by some transgender women as part of their gender-affirming care. This study will also assess if estradiol levels in blood vary between boosted and unboosted HIV medicines when transgender women...

Pages